COX‐2 in lung cancer: Mechanisms, development, and targeted therapies
Abstract Lung cancer (LC) is the leading cause of cancer‐related death worldwide, with non‐small cell lung cancer (NSCLC) comprising 85% of all cases. COX‐2, an enzyme induced significantly under stress conditions, catalyzes the conversion of free arachidonic acid into prostaglandins. It exhibits hi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Chronic Diseases and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cdt3.120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184120838127616 |
|---|---|
| author | Xueqi Liu Junli Zhang Wenwu Sun Jianping Cao Zhuang Ma |
| author_facet | Xueqi Liu Junli Zhang Wenwu Sun Jianping Cao Zhuang Ma |
| author_sort | Xueqi Liu |
| collection | DOAJ |
| description | Abstract Lung cancer (LC) is the leading cause of cancer‐related death worldwide, with non‐small cell lung cancer (NSCLC) comprising 85% of all cases. COX‐2, an enzyme induced significantly under stress conditions, catalyzes the conversion of free arachidonic acid into prostaglandins. It exhibits high expression in various tumors and is closely linked to LC progression. COX‐2 functions as a pivotal driver in cancer pathogenesis by promoting prostaglandin E2 synthesis and facilitating tumor cell occurrence and development. Furthermore, COX‐2 holds potential as a predictive marker for early‐stage NSCLC, guiding targeted therapy in patients with early COX‐2 overexpression. Additionally, combining COX‐2 inhibitors with diverse treatment modalities enhances tumor therapeutic efficacy, minimizes adverse effects on healthy tissues, and improves overall patient survival rates posttreatment. In conclusion, combined therapy targeting COX‐2 presents a promising novel strategy for NSCLC treatment, offering avenues for improving prognosis and effective tumor treatment. This review provides novel insights and ideas for developing new treatment strategies to improve the prognosis of NSCLC. |
| format | Article |
| id | doaj-art-386d56cc59d44a4db9196c8ba5330fa8 |
| institution | OA Journals |
| issn | 2589-0514 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Chronic Diseases and Translational Medicine |
| spelling | doaj-art-386d56cc59d44a4db9196c8ba5330fa82025-08-20T02:17:08ZengWileyChronic Diseases and Translational Medicine2589-05142024-12-0110428129210.1002/cdt3.120COX‐2 in lung cancer: Mechanisms, development, and targeted therapiesXueqi Liu0Junli Zhang1Wenwu Sun2Jianping Cao3Zhuang Ma4Department of Respiratory Medicine Postgraduate Training Base of Jinzhou Medical University in the General Hospital of Northern Theater Command Shenyang Liaoning ChinaDepartment of Respiratory Medicine General Hospital of Northern Theater Command Shenyang Liaoning ChinaDepartment of Respiratory Medicine General Hospital of Northern Theater Command Shenyang Liaoning ChinaDepartment of Respiratory Medicine General Hospital of Northern Theater Command Shenyang Liaoning ChinaDepartment of Respiratory Medicine General Hospital of Northern Theater Command Shenyang Liaoning ChinaAbstract Lung cancer (LC) is the leading cause of cancer‐related death worldwide, with non‐small cell lung cancer (NSCLC) comprising 85% of all cases. COX‐2, an enzyme induced significantly under stress conditions, catalyzes the conversion of free arachidonic acid into prostaglandins. It exhibits high expression in various tumors and is closely linked to LC progression. COX‐2 functions as a pivotal driver in cancer pathogenesis by promoting prostaglandin E2 synthesis and facilitating tumor cell occurrence and development. Furthermore, COX‐2 holds potential as a predictive marker for early‐stage NSCLC, guiding targeted therapy in patients with early COX‐2 overexpression. Additionally, combining COX‐2 inhibitors with diverse treatment modalities enhances tumor therapeutic efficacy, minimizes adverse effects on healthy tissues, and improves overall patient survival rates posttreatment. In conclusion, combined therapy targeting COX‐2 presents a promising novel strategy for NSCLC treatment, offering avenues for improving prognosis and effective tumor treatment. This review provides novel insights and ideas for developing new treatment strategies to improve the prognosis of NSCLC.https://doi.org/10.1002/cdt3.120COX‐2lung cancerPGE2targeted therapytumor development |
| spellingShingle | Xueqi Liu Junli Zhang Wenwu Sun Jianping Cao Zhuang Ma COX‐2 in lung cancer: Mechanisms, development, and targeted therapies Chronic Diseases and Translational Medicine COX‐2 lung cancer PGE2 targeted therapy tumor development |
| title | COX‐2 in lung cancer: Mechanisms, development, and targeted therapies |
| title_full | COX‐2 in lung cancer: Mechanisms, development, and targeted therapies |
| title_fullStr | COX‐2 in lung cancer: Mechanisms, development, and targeted therapies |
| title_full_unstemmed | COX‐2 in lung cancer: Mechanisms, development, and targeted therapies |
| title_short | COX‐2 in lung cancer: Mechanisms, development, and targeted therapies |
| title_sort | cox 2 in lung cancer mechanisms development and targeted therapies |
| topic | COX‐2 lung cancer PGE2 targeted therapy tumor development |
| url | https://doi.org/10.1002/cdt3.120 |
| work_keys_str_mv | AT xueqiliu cox2inlungcancermechanismsdevelopmentandtargetedtherapies AT junlizhang cox2inlungcancermechanismsdevelopmentandtargetedtherapies AT wenwusun cox2inlungcancermechanismsdevelopmentandtargetedtherapies AT jianpingcao cox2inlungcancermechanismsdevelopmentandtargetedtherapies AT zhuangma cox2inlungcancermechanismsdevelopmentandtargetedtherapies |